SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Neoleukin Therapeutics, Inc. (NLTX) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 28/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NLTX
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-8.65 |
$0.00 |
$-21.86M |
- |
| 2016 |
$-9.79 |
$0.00 |
$-37M |
- |
| 2017 |
$-10.70 |
$0.00 |
$-50.18M |
- |
| 2018 |
$-1.34 |
$25M |
$-31.59M |
-126.3% |
| 2019 |
$-12.85 |
$0.00 |
$-69.44M |
- |
| 2020 |
$-3.20 |
$451K |
$-33.28M |
-7378.5% |
| 2021 |
$-5.50 |
$6K |
$-60.69M |
-1011533.3% |
| 2022 |
$-5.07 |
$0.00 |
$-57.56M |
- |
| 2024 |
$-3.96 |
$0.00 |
$-75.14M |
- |
| 2025 |
$0.00 |
$0.00 |
$-90.35M |
- |
